ICER posts draft scoping document for the assessment of treatments for non-alcoholic steatohepatitis

ICER

30 October 2019 - Document open to public comment until 20 November 20 2019.

The Institute for Clinical and Economic Review (ICER) has posted a Draft Scoping Document outlining a planned review of the comparative clinical effectiveness and value of obeticholic acid (Intercept Pharmaceuticals), which will be indicated for non-alcoholic steatohepatitis (NASH). ICER previously reviewed obeticholic acid for the treatment of NASH in July 2016.

All interested stakeholders are encouraged to submit comments and suggested refinements to the scope to ensure all perspectives are adequately considered. Comments can be submitted by email to publiccomments@icer-review.org and must be received by 5 PM ET on 20 November 2019. All comments submitted must meet ICER's formatting specifications.

Read ICER Announcement

Michael Wonder

Posted by:

Michael Wonder